 |
 |
 |
 |
|
 |
Les informations publiées par la revue Prescrire
présentent un intérêt bien au delà des
limites de la francophonie. Cest pourquoi lAssociation
Mieux Prescrire a décidé de publier régulièrement,
depuis 1992, des sélections de textes de la revue Prescrire
en anglais, langue la plus utilisée aujourdhui par la
communauté médicale et pharmaceutique mondiale.
Prescrire International regroupe, tous les deux mois, une sélection
de textes de la revue Prescrire, minutieusement traduits en anglais
par des professionnels anglophones, sous le contrôle de la Rédaction
de la revue Prescrire.
Labonnement dun an à Prescrire International comprend
la livraison de 6 numéros de 40 pages et dun
index détaillé couvrant les 5 dernières
années.
Les abonnés à Prescrire International, répartis
dans près de 70 pays, sont parfois des praticiens de terrain,
mais le plus souvent des "personnes relais" (universitaires,
responsables dassociations de formation, de centres de documentation,
dagences administratives ou dévaluation du médicament,
etc.). |
 |
 |
 |
| Prescrire International is the concise, English language
version of la revue Prescrire. Prescrire International is a unique
source of independent comparative information on drugs and other therapeutic
interventions. The New Drugs section provides you with comparative
assessments of new drugs and news indications. The Reviews section
gives you assessments of therapeutic interventions as well as treatment
guidelines that will help you to offer your patients effective care
based on the best availabe evidence. The Adverse Effects section gives
you a balanced view of the latest suspected or confirmed adverse drug
reaction data collected from the many published and unpublished data
sources all over the world. |
 |
 |
 |
| Prescrire International n°96, August
2008 |
 |
Editorial
The constant practitioner
Resist the urge to overmedicate (p.134) |
|
 |
New Products
Raltegravir (in multidrug-resistant HIV)
Alternative to enfuvirtide/darunavir (p.135) |
|
 |
Adalimumab (severe Crohn's disease)
A second TNF alpha antagonist (p.137) |
|
 |
Metformin (dispersible tablets)
A welcome formulation (p.138) |
|
 |
Solostar° pen for glargine and glulisine insulins
Less convenient than Innolet° pen (p.138) |
|
 |
Inhaled insulin no longer marketed
Welcome news (p.139) |
|
 |
| Inhaled insulin and lung cancer (p.139) |
|
 |
Kaletra° oral solution
Modification of confusing label (p.140) |
|
 |
Zanamivir (in children over 5 years)
Influenza in children and adults: symptom relief or vaccination (p.141) |
|
 |
Common stems - INN
-tegravir (p.141) |
|
 |
Daily tadalafil
Beware medicalisation of human existence (p.142) |
|
 |
Zoledronic acid (postmenopausal osteoporosis)
No therapeutic advantage (p.143) |
|
 |
Betamethasone plaster
Just a useless gadget (p.144) |
|
 |
Infliximab (severe Crohn's disease in children)
Many unknowns (p.145) |
|
 |
Fentanyl by iontophoresis (postoperative analgesia)
A step backwards compared with intravenous morphine (p.146) |
|
 |
| Shortcuts. Dasatinib - carbetocin - rufinamide (p.149) |
|
 |
Adverse Effects
Colchicine: serious interactions (p.151) |
|
 |
| Death due to intrathecal vindesine (p.153) |
|
 |
| Isotretinoin and intestinal damage (p.154) |
|
 |
| SSRI antidepressants and persistent pulmonary hypertension
in newborns (p. 156) |
|
 |
| Iatrogenic burns: beware of microwaves! (p.157) |
|
 |
| Atrial-oesophageal fistula after radiofrequency ablation
(p.158) |
|
 |
| Cancer chemotherapy: sometimes takes the pleasure out
of eating (p.159) |
|
 |
| Clozapine: ileus (p.160) |
|
 |
| HPV 6, 11, 16, 18 vaccine: pharmacovigilance reports
in 2007 (p.160) |
|
 |
| Benzalkonium chloride: death of an asthmatic patient
(p.160) |
|
 |
| Bisphophonates and atrial fibrillation (p.161) |
|
 |
| Cysteamine: Ehlers-Danlos syndrome (p.161) |
|
 |
| Confusion and stroke due to an "umbrella brand"
product (p.161) |
|
 |
Reviews
Artemisinin derivatives and malaria
Prescrire's advice: Treatment of uncomplicated malaria attacks (p.162) |
|
 |
Intravenous artesunate for severe malaria
An alternative to intravenous quinine ( p.168) |
|
 |
Treatment of facial lipoatrophy in HIV-infected patients
Switching drugs, surgery or polylactic acid (p.170) |
|
 |
Outlook
Editorial
Distinguishing between research and clinical care (p.171) |
|
 |
Access
Artemisinin in Africa (p.172) |
|
 |
Prevention
Waterpipe smoking: risky, but increasingly popular (p.173) |
|
 |
Forum
The Advance trial and type 2 diabetes (continued) (p.173) |
|
 |
 |
 |
 |
 |